CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFα, and TGFβ

Gene Therapy

Volumn 10, Issue 3, 2003, Pages 198-205

  Bruning A ^a   Runnebaum, I B ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adenovirus; CAR; Dexamethasone; Gene therapy; Integrins; Tumor necrosis factor

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; BETA GALACTOSIDASE; BETA1 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; CELL ADHESION MOLECULE; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DEXAMETHASONE; INTEGRIN; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER GENETICS; CELL ADHESION; CLINICAL TRIAL; CONFOCAL MICROSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE TRANSFER; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HELA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATION; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VOMITING;

ADENOVIRIDAE; ANTI-INFLAMMATORY AGENTS; BETA-GALACTOSIDASE; CALCIUM-BINDING PROTEINS; CELL ADHESION; CYTOKINES; DEXAMETHASONE; EYE PROTEINS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HIPPOCALCIN; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; INTEGRINS; LIPOPROTEINS; NEOPLASMS; NERVE TISSUE PROTEINS; RECEPTORS, VITRONECTIN; RECOVERIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; EMESIS;

EID: 0037321159     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301887     Document Type: Review

References (31)

1. Bergelson JM et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
2. Carson SD, Chapman NN, Tracy SM. Purification of the putative coxsackie B virus receptor from Hela cells. Biochem Biophys Res Commun 1997; 233: 325-328.
3. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
4. Okegawa T et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031-5036.
5. Okegawa T et al. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001; 61: 6592-6600.
6. Pickles RJ et al. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol 2000; 74: 6050-6057.
7. Cohen CJ et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191-15196.
8. Buller RE et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with CHS 58500. Cancer Gene Ther 2002; 9: 553-566.
9. Buller RE et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 567-572.
10. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752-756.
11. Bewley MC et al. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999; 286: 1579-1583.
12. Nemerow GR, Stewart PL. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 1999; 63: 725-734.
13. Li Y et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-330.
14. Li D, Duan L, Freimuth P, O'Malley Jr BW. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5: 4175-4181.
15. Pearson AS et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 4208-4213.
16. Hutchin ME, Pickles RJ, Yarbrough WG. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum Gene Ther 2000; 11: 2365-2375.
17. Brüning A et al. Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin β3 subunit expression and increased by reconstitution of integrin αvβ3. Hum Gene Ther 2001; 12: 391-399.
18. Ignotz RA, Heino J, Massague J. Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1. J Biol Chem 1989; 264: 389-392.
19. Enenstein J, Waleh NS, Kramer RH. Basic FGF and TGF-beta differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992; 203: 499-503.
20. Kawashima A, Kawahara E, Tokuda R, Nakanishi I. Tumour necrosis factor-alpha provokes upregulation of alpha2beta1 and alpha5beta1 integrins, and cell migration in OST osteosarcoma cells. Cell Biol Int 2001; 25: 319-329.
21. Kaltschmidt B et al. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem 2000; 267: 3828-3835.
22. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032.
23. Bergelson JM et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419.
24. Nalbantoglu J, Pari G, Karpati G, Holland PC. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999; 10: 1009-1019.
25. Honda T et al. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res Mol Brain Res 2000; 77: 19-28.
26. Hidaka C et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103: 579-587.
27. Fechner H et al. Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 1520-1535.
28. Wickham TJ et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
29. Kanerva A et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
30. Wills KN et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 1994; 5: 1079-1088.
31. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 1988; 62: 1647-1652.